Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Net Cash Flow (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Net Cash Flow for 10 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 139.61% year-over-year to $8.3 million, compared with a TTM value of $28.6 million through Dec 2025, up 394.23%, and an annual FY2025 reading of $28.6 million, up 394.23% over the prior year.
  • Net Cash Flow was $8.3 million for Q4 2025 at Zevra Therapeutics, up from $6.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $71.7 million in Q1 2021 and bottomed at -$25.3 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $2.9 million, with a median of -$680500.0 recorded in 2021.
  • The sharpest move saw Net Cash Flow surged 7178.38% in 2021, then crashed 3577.5% in 2024.
  • Year by year, Net Cash Flow stood at -$19.2 million in 2021, then skyrocketed by 74.68% to -$4.8 million in 2022, then surged by 88.27% to -$569000.0 in 2023, then plummeted by 3577.5% to -$20.9 million in 2024, then surged by 139.61% to $8.3 million in 2025.
  • Business Quant data shows Net Cash Flow for ZVRA at $8.3 million in Q4 2025, $6.7 million in Q3 2025, and $9.7 million in Q2 2025.